Refractory metastatic Her2 positive breast cancer research hub

A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer

This study is looking at a new treatment for advanced breast cancer that has stopped responding to standard treatments. It checks how safe and effective a new cell therapy is when given with two existing medicines, trastuzumab and pertuzumab, for women with HER2-positive breast cancer.